

Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use

NCT04974645

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)

**Approval Period:** 04/13/2022 - 05/12/2022

<a href="#"><u>Modification Form</u></a>	2
<a href="#"><u>Personnel Info</u></a>	3
<a href="#"><u>Participant Population</u></a>	4
<a href="#"><u>Study Location</u></a>	5
<a href="#"><u>General Checklist</u></a>	5
<a href="#"><u>Funding</u></a>	7
<a href="#"><u>Resources</u></a>	8
<a href="#"><u>Purpose, Study Procedures</u></a>	10
<a href="#"><u>Radioisotopes or Radiation Machines</u></a>	15
<a href="#"><u>Drugs, Devices, Reagents</u></a>	16
<a href="#"><u>Medical Equipment for Human Subjects and Laboratory Animals</u></a>	17
<a href="#"><u>Participant Population(a-g)</u></a>	17
<a href="#"><u>Participant Population(h-m)</u></a>	19
<a href="#"><u>Risks(a-e)</u></a>	20
<a href="#"><u>Privacy And Confidentiality</u></a>	24
<a href="#"><u>Conflict Of Interest</u></a>	25
<a href="#"><u>Consent Background</u></a>	28
<a href="#"><u>Assent Background</u></a>	30
<a href="#"><u>HIPAA Background</u></a>	30
<a href="#"><u>Attachments</u></a>	31
<a href="#"><u>Obligations</u></a>	34

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

### Modification

#### 1. Summarize your proposed changes.

0 participants enrolled to date. We intend to incorporate the knowledge gained from the pilot study (IRB 62053) for this study prior to starting recruitment.

Proposed changes below.

Resources: Section a has been updated. Ken Weingardt, Amer Raheemullah, and Ashley Lee have been removed.

Main Protocol Adjustments:

1) Removing PEth tests (biomarker of alcohol use) from the project. This affects General Checklist (#5), Resources section c on PO Box, Protocol Information sections 2a, 8, 9, 11, ICF.

2) Removing MINI interviews from the project. This affects section 2a, 8, 11, ICF.

3) Section 2a: Added potential recruitment sources (also affects Resources e, and section 8g). Added Data Flow wording from IRB 62053 (pilot study).

4) Section 3a background: Updated background info with preliminary data from pilot study (IRB 62053).

5) Sample size proposed for this study has been updated from 268 to 400. Sections 8a, 8k, 9d, ICF have been updated. Justification for increase in sample size: The team has decided not to use the data for the FDA as a pivotal trial. This decision simplifies the study consenting process (Part 11 and Adobe Sign) and the assessment schedule (i.e., dropping the PEth and MINI). These changes greatly reduce personnel time and research costs and enable us to direct resources to increasing the sample size to permit greater diversity in our sample and testing of subsample effects of interest (i.e., differences in treatment outcomes by gender, alcohol as the primary substance, and by race/ethnicity).

6) Section 8c updated with wording from IRB 62053 (pilot study).

7) Sections 8k, 13, 15, and 16 have been updated.

Section 16 attachment updates:

1) Updated documents to the version in IRB 62053: EdOnly Week 6 document, Debrief doc 7.21.21, DSMB Minutes and Slides from 6.16.21, Email template for Education Only Group Intervention Content

2) Removed documents related to the MINI and PEth test collection.

3) Updated questionnaires based on approved questionnaires (modified 7.22.21) from IRB 62053. Changes tracked.

4) Updated group instructions based on version in IRB 62053. Changes tracked.

5) Updated and added templates.

6) Attached additional recruitment materials.

7) Attached Woebot letter regarding 21 CFR Part 11 Compliance.

Consent form:

1) The ICF has been updated based on the approved ICF for IRB 62053 (pilot study).

2) Protocol Information Section 11a) Added line "Informed consent will utilize Stanford's Adobe Sign platform and procedures for part 11 compliance."

#### 2. Indicate Level of Risk

No Change

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**3. Update the Conflict of Interest (COI) section if any changes in COI have been made since the last protocol submission.**

N Is there a change in the conflicting interest status for any existing personnel on this protocol?

## Protocol Director

A horizontal bar chart with 10 bars. The bars are black and vary in length. The first bar is the shortest, followed by a medium-length bar. Then there is a group of three bars of increasing length. After a short gap, there is a group of four bars of increasing length. The final bar is the longest in the sequence.

## Admin Contact

A horizontal bar chart with four categories on the y-axis. The x-axis represents a value from 0 to 100. Each category has a total bar length of 100, divided into segments. The segments are colored black, white, and grey. The total length of the bars decreases from left to right.

Category	Segment 1 (Black)	Segment 2 (White)	Segment 3 (Grey)	Segment 4 (Black)	Segment 5 (White)	Segment 6 (Grey)	Segment 7 (Black)	Segment 8 (White)	Segment 9 (Grey)	Segment 10 (Black)	Segment 11 (White)	Segment 12 (Grey)	Segment 13 (Black)	Segment 14 (White)	Segment 15 (Grey)	Segment 16 (Black)	Segment 17 (White)	Segment 18 (Grey)	Segment 19 (Black)	Segment 20 (White)	Segment 21 (Grey)	Segment 22 (Black)	Segment 23 (White)	Segment 24 (Grey)	Segment 25 (Black)	Segment 26 (White)	Segment 27 (Grey)	Segment 28 (Black)	Segment 29 (White)	Segment 30 (Grey)	Segment 31 (Black)	Segment 32 (White)	Segment 33 (Grey)	Segment 34 (Black)	Segment 35 (White)	Segment 36 (Grey)	Segment 37 (Black)	Segment 38 (White)	Segment 39 (Grey)	Segment 40 (Black)	Segment 41 (White)	Segment 42 (Grey)	Segment 43 (Black)	Segment 44 (White)	Segment 45 (Grey)	Segment 46 (Black)	Segment 47 (White)	Segment 48 (Grey)	Segment 49 (Black)	Segment 50 (White)	Segment 51 (Grey)	Segment 52 (Black)	Segment 53 (White)	Segment 54 (Grey)	Segment 55 (Black)	Segment 56 (White)	Segment 57 (Grey)	Segment 58 (Black)	Segment 59 (White)	Segment 60 (Grey)	Segment 61 (Black)	Segment 62 (White)	Segment 63 (Grey)	Segment 64 (Black)	Segment 65 (White)	Segment 66 (Grey)	Segment 67 (Black)	Segment 68 (White)	Segment 69 (Grey)	Segment 70 (Black)	Segment 71 (White)	Segment 72 (Grey)	Segment 73 (Black)	Segment 74 (White)	Segment 75 (Grey)	Segment 76 (Black)	Segment 77 (White)	Segment 78 (Grey)	Segment 79 (Black)	Segment 80 (White)	Segment 81 (Grey)	Segment 82 (Black)	Segment 83 (White)	Segment 84 (Grey)	Segment 85 (Black)	Segment 86 (White)	Segment 87 (Grey)	Segment 88 (Black)	Segment 89 (White)	Segment 90 (Grey)	Segment 91 (Black)	Segment 92 (White)	Segment 93 (Grey)	Segment 94 (Black)	Segment 95 (White)	Segment 96 (Grey)	Segment 97 (Black)	Segment 98 (White)	Segment 99 (Grey)	Segment 100 (Black)	Segment 101 (White)	Segment 102 (Grey)	Segment 103 (Black)	Segment 104 (White)	Segment 105 (Grey)	Segment 106 (Black)	Segment 107 (White)	Segment 108 (Grey)	Segment 109 (Black)	Segment 110 (White)	Segment 111 (Grey)	Segment 112 (Black)	Segment 113 (White)	Segment 114 (Grey)	Segment 115 (Black)	Segment 116 (White)	Segment 117 (Grey)	Segment 118 (Black)	Segment 119 (White)	Segment 120 (Grey)	Segment 121 (Black)	Segment 122 (White)	Segment 123 (Grey)	Segment 124 (Black)	Segment 125 (White)	Segment 126 (Grey)	Segment 127 (Black)	Segment 128 (White)	Segment 129 (Grey)	Segment 130 (Black)	Segment 131 (White)	Segment 132 (Grey)	Segment 133 (Black)	Segment 134 (White)	Segment 135 (Grey)	Segment 136 (Black)	Segment 137 (White)	Segment 138 (Grey)	Segment 139 (Black)	Segment 140 (White)	Segment 141 (Grey)	Segment 142 (Black)	Segment 143 (White)	Segment 144 (Grey)	Segment 145 (Black)	Segment 146 (White)	Segment 147 (Grey)	Segment 148 (Black)	Segment 149 (White)	Segment 150 (Grey)	Segment 151 (Black)	Segment 152 (White)	Segment 153 (Grey)	Segment 154 (Black)	Segment 155 (White)	Segment 156 (Grey)	Segment 157 (Black)	Segment 158 (White)	Segment 159 (Grey)	Segment 160 (Black)	Segment 161 (White)	Segment 162 (Grey)	Segment 163 (Black)	Segment 164 (White)	Segment 165 (Grey)	Segment 166 (Black)	Segment 167 (White)	Segment 168 (Grey)	Segment 169 (Black)	Segment 170 (White)	Segment 171 (Grey)	Segment 172 (Black)	Segment 173 (White)	Segment 174 (Grey)	Segment 175 (Black)	Segment 176 (White)	Segment 177 (Grey)	Segment 178 (Black)	Segment 179 (White)	Segment 180 (Grey)	Segment 181 (Black)	Segment 182 (White)	Segment 183 (Grey)	Segment 184 (Black)	Segment 185 (White)	Segment 186 (Grey)	Segment 187 (Black)	Segment 188 (White)	Segment 189 (Grey)	Segment 190 (Black)	Segment 191 (White)	Segment 192 (Grey)	Segment 193 (Black)	Segment 194 (White)	Segment 195 (Grey)	Segment 196 (Black)	Segment 197 (White)	Segment 198 (Grey)	Segment 199 (Black)	Segment 200 (White)	Segment 201 (Grey)	Segment 202 (Black)	Segment 203 (White)	Segment 204 (Grey)	Segment 205 (Black)	Segment 206 (White)	Segment 207 (Grey)	Segment 208 (Black)	Segment 209 (White)	Segment 210 (Grey)	Segment 211 (Black)	Segment 212 (White)	Segment 213 (Grey)	Segment 214 (Black)	Segment 215 (White)	Segment 216 (Grey)	Segment 217 (Black)	Segment 218 (White)	Segment 219 (Grey)	Segment 220 (Black)	Segment 221 (White)	Segment 222 (Grey)	Segment 223 (Black)	Segment 224 (White)	Segment 225 (Grey)	Segment 226 (Black)	Segment 227 (White)	Segment 228 (Grey)	Segment 229 (Black)	Segment 230 (White)	Segment 231 (Grey)	Segment 232 (Black)	Segment 233 (White)	Segment 234 (Grey)	Segment 235 (Black)	Segment 236 (White)	Segment 237 (Grey)	Segment 238 (Black)	Segment 239 (White)	Segment 240 (Grey)	Segment 241 (Black)	Segment 242 (White)	Segment 243 (Grey)	Segment 244 (Black)	Segment 245 (White)	Segment 246 (Grey)	Segment 247 (Black)	Segment 248 (White)	Segment 249 (Grey)	Segment 250 (Black)	Segment 251 (White)	Segment 252 (Grey)	Segment 253 (Black)	Segment 254 (White)	Segment 255 (Grey)	Segment 256 (Black)	Segment 257 (White)	Segment 258 (Grey)	Segment 259 (Black)	Segment 260 (White)	Segment 261 (Grey)	Segment 262 (Black)	Segment 263 (White)	Segment 264 (Grey)	Segment 265 (Black)	Segment 266 (White)	Segment 267 (Grey)	Segment 268 (Black)	Segment 269 (White)	Segment 270 (Grey)	Segment 271 (Black)	Segment 272 (White)	Segment 273 (Grey)	Segment 274 (Black)	Segment 275 (White)	Segment 276 (Grey)	Segment 277 (Black)	Segment 278 (White)	Segment 279 (Grey)	Segment 280 (Black)	Segment 281 (White)	Segment 282 (Grey)	Segment 283 (Black)	Segment 284 (White)	Segment 285 (Grey)	Segment 286 (Black)	Segment 287 (White)	Segment 288 (Grey)	Segment 289 (Black)	Segment 290 (White)	Segment 291 (Grey)	Segment 292 (Black)	Segment 293 (White)	Segment 294 (Grey)	Segment 295 (Black)	Segment 296 (White)	Segment 297 (Grey)	Segment 298 (Black)	Segment 299 (White)	Segment 300 (Grey)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
Category 1	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	190	200	210	220	230	240	250	260	270	280	290	300	310	320	330	340	350	360	370	380	390	400	410	420	430	440	450	460	470	480	490	500	510	520	530	540	550	560	570	580	590	600	610	620	630	640	650	660	670	680	690	700	710	720	730	740	750	760	770	780	790	800	810	820	830	840	850	860	870	880	890	900	910	920	930	940	950	960	970	980	990	1000	1010	1020	1030	1040	1050	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250	1260	1270	1280	1290	1300	1310	1320	1330	1340	1350	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	1500	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650	1660	1670	1680	1690	1700	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800	1810	1820	1830	1840	1850	1860	1870	1880	1890	1900	1910	1920	1930	1940	1950	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050	2060	2070	2080	2090	2100	2110	2120	2130	2140	2150	2160	2170	2180	2190	2200	2210	2220	2230	2240	2250	2260	2270	2280	2290	2300	2310	2320	2330	2340	2350	2360	2370	2380	2390	2400	2410	2420	2430	2440	2450	2460	2470	2480	2490	2500	2510	2520	2530	2540	2550	2560	2570	2580	2590	2600	2610	2620	2630	2640	2650	2660	2670	2680	2690	2700	2710	2720	2730	2740	2750	2760	2770	2780	2790	2800	2810	2820	2830	2840	2850	2860	2870	2880	2890	2900	2910	2920	2930	2940	2950	2960	2970	2980	2990	3000	3010	3020	3030	3040	3050	3060	3070	3080	3090	3100	3110	3120	3130	3140	3150	3160	3170	3180	3190	3200	3210	3220	3230	3240	3250	3260	3270	3280	3290	3300	3310	3320	3330	3340	3350	3360	3370	3380	3390	3400	3410	3420	3430	3440	3450	3460	3470	3480	3490	3500	3510	3520	3530	3540	3550	3560	3570	3580	3590	3600	3610	3620	3630	3640	3650	3660	3670	3680	3690	3700	3710	3720	3730	3740	3750	3760	3770	3780	3790	3800	3810	3820	3830	3840	3850	3860	3870	3880	3890	3900	3910	3920	3930	3940	3950	3960	3970	3980	3990	4000	4010	4020	4030	4040	4050	4060	4070	4080	4090	4100	4110	4120	4130	4140	4150	4160	4170	4180	4190	4200	4210	4220	4230	4240	4250	4260	4270	4280	4290	4300	4310	4320	4330	4340	4350	4360	4370	4380	4390	4400	4410	4420	4430	4440	4450	4460	4470	4480	4490	4500	4510	4520	4530	4540	4550	4560	4570	4580	4590	4600	4610	4620	4630	4640	4650	4660	4670	4680	4690	4700	4710	4720	4730	4740	4750	4760	4770	4780	4790	4800	4810	4820	4830	4840	4850	4860	4870	4880	4890	4900	4910	4920	4930	4940	4950	4960	4970	4980	4990	5000	5010	5020	5030	5040	5050	5060	5070	5080	5090	5100	5110	5120	5130	5140	5150	5160	5170	5180	5190	5200	5210	5220	5230	5240	5250	5260	5270	5280	5290	5300	5310	5320	5330	5340	5350	5360	5370	5380	5390	5400	5410	5420	5430	5440	5450	5460	5470	5480	5490	5500	5510	5520	5530	5540	5550	5560	5570	5580	5590	5600	5610	5620	5630	5640	5650	5660	5670	5680	5690	5700	5710	5720	5730	5740	5750	5760	5770	5780	5790	5800	5810	5820	5830	5840	5850	5860	5870	5880	5890	5900	5910	5920	5930	5940	5950	5960	5970	5980	5990	6000	6010	6020	6030	6040	6050	6060	6070	6080	6090	6100	6110	6120	6130	6140	6150	6160	6170	6180	6190	6200	6210	6220	6230	6240	6250	6260	6270	6280	6290	6300	6310	6320	6330	6340	6350	6360	6370	6380	6390	6400	6410	6420	6430	6440	6450	6460	6470	6480	6490	6500	6510	6520	6530	6540	6550	6560	6570	6580	6590	6600	6610	6620	6630	6640	6650	6660	6670	6680	6690	6700	6710	6720	6730	6740	6750	6760	6770	6780	6790	6800	6810	6820	6830	6840	6850	6860	6870	6880	6890	6900	6910	6920	6930	6940	6950	6960	6970	6980	6990	7000	7010	7020	7030	7040	7050	7060	7070	7080	7090	7100	7110	7120	7130	7140	7150	7160	7170	7180	7190	7200	7210	7220	7230	7240	7250	7260	7270	7280	7290	7300	7310	7320	7330	7340	7350	7360	7370	7380	7390	7400	7410	7420	7430	7440	7450	7460	7470	7480	7490	7500	7510	7520	7530	7540	7550	7560	7570	7580	7590	7600	7610	7620	7630	7640	7650	7660	7670	7680	7690	7700	7710	7720	7730	7740	7750	7760	7770	7780	7790	7800	7810	7820	7830	7840	7850	7860	7870	7880	7890	7900	7910	7920	7930	7940	7950	7960	7970	7980	7990	8000	8010	8020	8030	8040	8050	8060	8070	8080	8090	8100	8110	8120	8130	8140	8150	8160	8170	8180	8190	8200	8210	8220	8230	8240	8250	8260	8270	8280	8290	8300	8310	8320	8330	8340	8350	8360	8370	8380	8390	8400	8410	8420	8430	8440	8450	8460	8470	8480	8490	8500	8510	8520	8530	8540	8550	8560	8570	8580	8590	8600	8610	8620	8630	8640	8650	8660	8670	8680	8690	8700	8710	8720	8730	8740	8750	8760	8770	8780	8790	8800	8810	8820	8830	8840	8850	8860	8870	8880	8890	8900	8910	8920	8930	8940	8950	8960	8970	8980	8990	9000	9010	9020	9030	9040	9050	9060	9070	9080	9090	9100	9110	9120	9130	9140	9150	9160	9170	9180	9190	9200	9210	9220	9230	9240	9250	9260	9270	9280	9290	9300	9310	9320	9330	9340	9350	9360	9370	9380	9390	9400	9410	9420	9430	9440	9450	9460	9470	9480	9490	9500	9510	9520	9530	9540	9550	9560	9570	9580	9590	9600	9610	9620	9630	9640	9650	9660	9670	9680	9690	9700	9710	9720	9730	9740	9750	9760

## Investigator

Name	Degree (Program/year if student)	Position, e.g. Assistant Professor, Resident, etc.
Department	Phone	E-mail
CITI Training current		

## Other Contact

Name			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

## Academic Sponsor

Name	Degree (Program/year if student)	Position, e.g. Assistant Professor, Resident, etc.
------	----------------------------------	--

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Department		Phone		E-mail
<b>CITI Training current</b>				

## Other Personnel

The figure consists of a 10x3 grid of horizontal bar charts. Each row contains three bar charts with black bars of varying lengths. The bars are positioned in a staggered pattern across the columns. The length of the bars in each row increases from left to right. The first row has 3 bars, the second has 6, the third has 9, the fourth has 12, the fifth has 15, the sixth has 18, the seventh has 21, the eighth has 24, the ninth has 27, and the tenth has 30 bars respectively. The bars are black on a white background.

## Participant Population(s) Checklist

**Yes/No**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

- Children (under 18) N
- Pregnant Women and Fetuses N
- Neonates (0 - 28 days) N
- Abortuses N
- Impaired Decision Making Capacity N
- Cancer Subjects N
- Laboratory Personnel N
- Healthy Volunteers N
- Students N
- Employees N
- Prisoners N
- Other (i.e., any population that is not specified above) Y
- International Participants N

Please enter the countries separated by comma

### Study Location(s) Checklist

Yes/No

- Stanford University Y
- Clinical & Translational Research Unit (CTRU)
- Stanford Hospital and Clinics
- Lucile Packard Children's Hospital (LPCH)
- VAPAHCS (Specify PI at VA)
- Other (Click ADD to specify details)

### General Checklist

#### Multi-site

Yes/No

- Is this a multi-site study? A multi-site study is generally a study that involves one or more medical or research institutions in which one site takes a lead role.(e.g., multi-site clinical trial)

N

### Collaborating Institution(s)

Yes/No

- Are there any collaborating institution(s)? A collaborating institution is generally an institution that collaborates equally on a research endeavor with one or more institutions.

Y

Institution Name	Contact Name	Contact Phone	Contact Email	Permission?	Engaged?
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**Cancer Institute** **Yes/No**

- Cancer-Related Studies (studies with cancer endpoints), Cancer Subjects (e.g., clinical trials, behavior/prevention) or Cancer Specimens (e.g., blood, tissue, cells, body fluids with a scientific hypothesis stated in the protocol). N

**Clinical Trials** **Yes/No**

- Investigational drugs, biologics, reagents, or chemicals? N
  - Commercially available drugs, reagents, or other chemicals administered to subjects (even if they are not being studied)? N
  - Investigational Device / Commercial Device used off-label? Y
  - IDE Exempt Device (Commercial Device used according to label, Investigational In Vitro Device or Assay, or Consumer Preference/Modifications/Combinations of Approved Devices) N
  - Will this study be registered on# clinicaltrials.gov? ( See Stanford decision tree ) Y
  - Who will register for ClinicalTrials.gov? N
- NCT#

**Tissues and Specimens** **Yes/No**

- Human blood, cells, tissues, or body fluids (tissues)? N
- Tissues to be stored for future research projects? N
- Tissues to be sent out of this institution as part of a research agreement? For guidelines, please see <https://sites.stanford.edu/ico/mtas> N

**Biosafety (APB)** **Yes/No**

- Are you submitting a Human Gene Transfer investigation using a biological agent or recombinant DNA vector? Please review the Administrative Panel on BioSafety website for more information. N
- Are you submitting a Human study using biohazardous/infectious agents? If yes, refer to the Administrative Panel on BioSafety website prior to performing studies. N
- Are you submitting a Human study using samples from subjects that are known or likely to contain biohazardous/infectious agents? If yes, refer to the Administrative Panel on BioSafety website prior to performing studies. N

**Human Embryos or Stem Cells** **Yes/No**

- Human Embryos or Gametes? N
- Human Stem Cells (including hESC, iPSC, cancer stem cells, progenitor cells) N

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**Veterans Affairs (VA)** **Yes/No**

- The research recruits participants at the Veterans Affairs Palo Alto Health Care System(VAPAHCS). N
- The research involves the use of VAPAHCS non-public information to identify or contact human research participants or prospective subjects or to use such data for research purposes. N
- The research is sponsored (i.e., funded) by VAPAHCS. N
- The research is conducted by or under the direction of any employee or agent of VAPAHCS (full-time, part-time, intermittent, consultant, without compensation (WOC), on-station fee-basis, on-station contract, or on-station sharing agreement basis) in connection with her/his VAPAHCS responsibilities. N
- The research is conducted using any property or facility of VAPAHCS. N

**Equipment** **Yes/No**

- Use of Patient related equipment? If Yes, equipment must meet the standards established by Hospital Instrumentation and Electrical Safety Committee (650-725-5000) N
- Medical equipment used for human patients/subjects also used on animals? N
- Radioisotopes/radiation-producing machines, even if standard of care? N  
[http://www.stanford.edu/dept/EHS/prod/researchlab/radlaser/Human\\_use\\_guide.pdf](http://www.stanford.edu/dept/EHS/prod/researchlab/radlaser/Human_use_guide.pdf) More Info

**Payment** **Yes/No**

- Subjects will be paid/reimbursed for participation? See payment considerations. Y

**Funding** **Yes/No**

- Training Grant? N
- Program Project Grant? N
- Federally Sponsored Project? Y
- <https://doresearch.stanford.edu/policies/research-policy-handbook/definitions-and-types-agreements/specialized-categories-sponsored-industry-sponsored-clinical-trials>? Y

**Funding**

<b>Funding - Grants/Contracts</b>			
<b>Funding Administered By :</b>	STANFORD	<b>SPO # (if available) :</b>	138716
<b>Grant # (if available) :</b>		<b>Funded By (include pending) :</b>	NIH Prime Woebot
<b>Principal Investigator :</b>	Judith Prochaska		

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**Grant/Contract Title if different from Protocol Title :**

RCT of Woebot for Treating Substance Use Disorders

Y For Federal projects, are contents of this protocol consistent with the Federal proposal?

N Is this a Multiple Project Protocol (MPP)?


N Is this protocol under a MPP?

**Funding - Fellowships****Gift Funding****Dept. Funding****Other Funding****Resources :****a) Qualified staff.**

**Please state and justify the number and qualifications of your study staff.**



**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022



The staff are well versed in the ethics and rigorous methods of conducting research trials with human subjects. The staff are responsible for recruitment and consenting, assessments, treatment delivery, and follow-up activities.

**b) Training.**

**Describe the training you will provide to ensure that all persons assisting with the research are informed about the protocol and their research-related duties and functions.**

All study staff maintain up-to-date CITI certification and current knowledge of the research literature on use of digital health technologies for health behavior change.

**c) Facilities.**

**Please describe and justify.**

Dr. Prochaska has a faculty office at Stanford University in the Medical School Office Building with full computing resources needed for the trial.

All study data are gathered on a HIPAA compliant web platform that resides behind Stanford security firewalls and has been tried and tested by the University for several years, thus actual risk from data breach for study data is low.

**d) Sufficient time.**

**Explain whether you will have sufficient time to conduct and complete the research. Include how much time is required.**

Dr. Prochaska's faculty time is 100% devoted to research and this is one of her funded projects to which she dedicates her time.

**e) Access to target population.**

**Explain and justify whether you will have access to a population that will allow recruitment of the required number of participants.**

This NIDA-funded project is a collaboration with Woebot, a technology start up that is using artificial intelligence (AI) in a bot to deliver tailored messaging to improve mental health.

Participants will be recruited through a wide variety of strategies including but not limited to paid online advertising (e.g., sidebar Gmail and Yahoo advertisements); third party vendors such as Qualtrics panels, Clara Health, Map & Story, Splash Clinical; flyers; social media; free online and email advertising (e.g., Dr Prochaska's laboratory webpage, email listservs of digital health companies and the Stanford University student, faculty, and staff community); participants from previous studies who have interest in other studies; and national outpatient clinics with substance abuse programming including Stanford's Department of Psychiatry and Behavioral Sciences' Dual Diagnosis Clinic.

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Dr. Prochaska's team has extensive experience in recruiting research participants who use substances, including for online studies and has published on best practices.

**f) Access to resources if needed as a consequence of the research.**

**State whether you have medical or psychological resources available that participants might require as a consequence of the research when applicable. Please describe these resources.**

Study informed consent will state that Woebot (the app being used to deliver the intervention) is not a crisis program designed to address active suicidal ideation or overdose. Woebot also conversationally informs first time users that it is not a crisis service. Our current safety net protocol will be adapted for this study. Woebot detects crisis language and asks to confirm it with the user. If the user confirms, Woebot offers resources (911, suicide crisis hotlines), carefully curated with expert consultation. Our data indicate that users do not use Woebot for crisis management; about 6.3% trigger the safety net protocol, with 27% confirming that it is indeed a crisis when Woebot asks to confirm (i.e., our true positive rate). To make sure that we do not miss any cases, we over detect, rather than under detect. In addition, we periodically check the data for true/false positive rates.

Foreseeable risks to subjects include the possibility that some assessment questions and/or treatment procedures may be upsetting to subjects. Experience at Stanford with similar populations has indicated that the risk of emotional upset during the assessments is low and if it occurred, the upset would likely not be serious in nature and temporary. Such risks will be minimized by the thoughtful selection of questionnaires. Potential participants will also be informed that they may drop out of the study at any time and if requested, appropriate treatment referrals would then be given.

**g) Lead Investigator or Coordinating Institution in Multi-site Study.**

**Please explain (i) your role in coordinating the studies, (ii) procedures for routine communication with other sites, (iii) documentation of routine communications with other sites, (iv) planned management of communication of adverse outcomes, unexpected problems involving risk to participants or others, protocol modifications or interim findings.**

**1. Purpose**

**a) In layperson's language state the purpose of the study in 3-5 sentences.**

This study aims to validate W-SUDs as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to an education-only control condition, which has no cognitive behavioral therapy and the content is not delivered through a conversational user interface.

**b) State what the Investigator(s) hope to learn from the study. Include an assessment of the importance of this new knowledge.**

The COVID-19 pandemic introduced significant, unprecedented, and immediate psychological challenges to all, including individuals with substance use disorders (SUDs). The impact upon individuals with SUDs will be multifaceted and far reaching. In terms of physical health, experts postulate that individuals with SUDs may be at greater risk of mortality from COVID-19 given the variety of pre-existing physical health conditions this group has traditionally faced (i.e., COPD, cardiovascular disease, general poor respiratory health). In addition, the pandemic will beget significant emotional and psychiatric disruption from the multifaceted impact of the

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)

**Approval Period:** 04/13/2022 - 05/12/2022

illness. Such responses may include large-scale grief, loneliness, fear, loss of life experiences, constrained or frank inability to work, financial instability, risk of contagion, overwhelmed hospitals, limited access to recovery programs and reduced or significantly changed mental health service provision from clinics.

Woebot, the landmark product released by Woebot Labs Inc. in 2017, is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation. Woebot for Substance Use Disorders (W-SUDs) is a 2 phase SBIR industry-academic partnership between Woebot Labs Inc. and Stanford University that aims to develop and evaluate the evidence of the novel digital therapeutic, delivered by an artificial intelligence (AI)-powered, automated conversational agent named Woebot which is embedded in the therapeutic W-SUDs.

Milestones for Phase I included the development (e.g., content and engineering) of W-SUDs and piloting its preliminary efficacy, feasibility and acceptability among n=101 individuals with SUD.

Phase I (N=101) has concluded and a manuscript is in submission. In this study, W-SUDs was feasible to deliver, engaging, and acceptable; and associated with significant improvements in substance use, confidence, cravings, depression, and anxiety. Study attrition was high.

The supplemental study (W-C19) is a randomized control trial with a wait-list control condition. This study aimed to expand understanding of W-SUDs' performance among users experiencing SUDs whilst contributing to our overall understanding of COVID-19's impact upon this population. The intervention had concluded with N=180 participants enrolled. Experiencing worsened mental health symptoms during COVID-19 was associated with more substance use problems and depression and anxiety symptoms. Pandemic disruptions may exacerbate preexisting substance use problems.

Phase II will evaluate the efficacy of W-SUDs in a large scale RCT relative to an education-only control condition. Primary outcomes will be measures of the quantity and frequency of substance use including, number of substance use occasions, heavy drinking days (if applicable), percent days abstinent. Additionally, phase II will evaluate whether W-SUDs results in a greater reduction in substance-related problems than Education Only control and explore: Does engagement with W-SUDs, relative to education-only control (a) improve symptoms of depression and anxiety (b) improve work productivity (i.e. reduce presenteeism/absenteeism), (c) reduce cravings, (d) improve situational confidence. Phase II will also allow the team to learn more about the population interested in digitally delivered interventions.

#### Impact

Immediate access to a digital therapeutic in a resource constrained, social distance healthcare ecosystem amidst growing psychological challenges in this already vulnerable and underserved population.

Elements of our W-C19 program have already been integrated into W-SUDs because we felt that it was timely and appropriate to address users' concerns about the pandemic and demonstrated that Woebot was 'intelligent' to the current crisis.

- c) **Explain why human subjects must be used for this project. (i.e. purpose of study is to test efficacy of investigational device in individuals with specific condition; purpose of study is to examine specific behavioral traits in humans in classroom or other environment)**

The purpose of this study is to test the efficacy of a mobile-application delivered substance use disorder intervention compared to an education only control group.

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

## 2. Study Procedures

- a) Please SUMMARIZE the research procedures, screening through closeout, which the human subject will undergo. Refer to sections in the protocol attached in section 16, BUT do not copy the clinical protocol. Be clear on what is to be done for research and what is part of standard of care.**

Updated consent forms and HIPAA authorization will be uploaded before the start of recruitment. Ads, questionnaires, etc. will be uploaded for review before recruitment begins.

Recruitment will be a joint effort by Stanford University and Woebot Labs. Woebot may communicate the research opportunity through social media channels, and third party recruitment groups (e.g. Splash Clinical, Map & Story, Clara Health). The Stanford team may recruit through Qualtrics panels, ResearchMatch, listservs, and contact participants from previous research studies who are interested in future studies. Working with Dr. Prochaska's research team at Stanford, the Woebot team will take part in mapping out message development for the intervention and Woebot's IT team will lead the app programming (including build and quality control/de-bugging). Woebot will collect user data via the Woebot app (automatic process), which will be provided to the Stanford team. The Woebot team will participate in disseminating the study findings via publications and presentations.

Participants from recruitment channels will go through and screening consent and eligibility screener, and if eligible, will be asked to participate in their randomized group for 8 weeks and answer questionnaires administered at the beginning, mid-intervention (4-week), end of intervention (8-week), and post intervention (12-week). Informed consent form will appear after screening eligible, and must be signed before the baseline survey can be accessed. Computer randomization will occur after the baseline survey, and instructions for their group will be sent out. Woebot will rely on Stanford University IRB for review of this study.

The Stanford team will lead the study evaluations including the study measures, data collection (baseline and follow-ups at the 4-week, 8-week, and 12-week/30 days post treatment marks), data analyses, and writing up of study findings for dissemination. Participants will be randomized to condition via the online assessment platform, which has the functionality to allow randomization to one of two groups. Those randomized to W-SUDs (group 1) or education control (group 2) will see a private, email or study-only page pertaining to their group. To minimize bias and maximize study validity, group blinding will be in place; Participants should not know what the other intervention involves. Instructions will be provided for each group. A study debrief regarding group blinding will be provided to participants after the final survey. If the final survey is not completed, the debrief will be provided a month after the final survey was due.

Woebot is responsible for app management, study payments (e.g. purchasing Amazon e-gift cards for participant compensation). Participant management is on the Stanford side, including sending out the compensation, kits, etc. If the participant ends up contacting Woebot about the app or for a study related question, that message is passed on to the Stanford team or answered by the Woebot team if they have the answers.

In order to better understand what specific W-SUDs content the participants like, Lesson Completion Rates and Content Rating Metrics will be analyzed. Descriptive statistics will be used for the following scales: Usage Rating Profile Intervention (UPRI)-Acceptability, Usage Rating Profile Intervention (UPRI)-Feasibility, and Client Satisfaction Questionnaire (CSQ-8). Such descriptive statistics will provide a summary index of how likable the content and program was overall. Tests involving statistical significance will be used to assess the intervention's impact from baseline to EOT.

Utilizing study results as described above, the research team will learn the efficacy of a digital substance use therapeutic compared to an education only control group.

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)

**Approval Period:** 04/13/2022 - 05/12/2022

The intent is to utilize and leverage what was learned in this study to provide an intervention in a time where in person services are discouraged and to see if the intervention is more beneficial than a nonactive treatment condition.

**Data flow:**

Participants provide data by completing surveys. The Stanford team is the recipient of this data. Emails are shared with the Woebot team for the interventions, payment, and cross-checking for intervention contamination (i.e. commercial Woebot app use, WSUDs program use but are supposed to be in Education only group). Intervention contamination information will be shared by Woebot to Stanford. Participants also provide data by interacting with the Woebot app. Woebot Labs will share user data with the Stanford team, who will link the data to survey responses. The Stanford team will analyze the data and then share analyzed data with the Woebot team.

**b) Explain how the above research procedures are the least risky that can be performed consistent with sound research design.**

Given that the research aims to enroll a low-treatment seeking population, we do not envisage that participation in the study will be associated with elevated risk.

However, some risk is always present in studies that involve human participants.

Such risk may include the following:

Risk from breach of protected health information.

Possibly the greatest risk is from a leak of health information. All study data are gathered on a HIPAA compliant web platform that resides behind Stanford security firewalls and has been tried and tested by the University for several years, thus actual risk from data breach for study data is low. In addition, the Woebot application encrypts all message data exchanged between service users and Woebot, and collects minimal protected health information. Emails are hashed and not kept along side message data so that they are not easily associated with each other. In addition, the product recently became compliant with General Data Protection Regulations (GDPR) in the European Union which entails a user-ownership model of data protections.

Risk from answering questions that may be emotionally upsetting. Experience at Stanford with similar populations has indicated that the risk of emotional upset during the assessments is low and if it occurred, the upset would likely not be serious in nature and temporary. Such risks will be minimized by the thoughtful selection of questionnaires. Potential participants will also be informed that they may drop out of the study at any time and if requested, appropriate treatment referrals would then be given.

Risk of treatment avoidance due to engagement with either of the randomized interventions. In both interventions it is explicitly stated in the consent form that the service should not be used in place of traditional treatment. In the case of the W-SUDs intervention, Woebot is designed to hold individuals accountable for pursuing additional options in conditions of unchanged symptoms for a prolonged amount of time (4 weeks). In addition, Woebot will invite the user to consider what seeking additional services would look like.

**c) State if deception will be used. If so, provide the rationale and describe debriefing procedures. Since you will not be fully informing the participant in your consent process and form, complete an**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**alteration of consent (in section 13). Submit a debriefing script (in section 16).**

There will be intervention group blinding to maximize validity and minimize bias (i.e. reducing factors may affect the study outcomes). The research team does not know if W-SUDs is more effective than an education only control group. Group blinding minimizes preconceived expectations for each group and behaviors as a result of those expectations. To keep the group blinding effective, the groups are not fully described in the consent form, the company involved is not named (will be obvious which is the new intervention since the company makes a digital therapeutic mobile app with a chat bot), and full details of the group intervention a participant is randomized to will be provided after randomization.

A debrief document is attached in Section 16 and will be provided to participants after their study period. For those who complete the final survey, it'll be provided by email soon after. For those who do not complete the final survey, the information will be provided by email a month after the final survey (at 12-weeks) is due. This is to allow sufficient opportunity for the final survey to be completed before the timing of the final survey is considered "late". No participant will be given the debrief after the intervention period at 8-weeks since the study will also be observing sustained change post-intervention (between 8-weeks and 12-weeks).

- d) State if audio or video recording will occur. Describe what will become of the recording after use, e.g., shown at scientific meetings, erased. Describe the final disposition of the recordings.**

No audio or video recordings will occur.

- e) Describe alternative procedures or courses of treatment, if any, that might be advantageous to the participant. Describe potential risks and benefits associated with these. Any standard treatment that is being withheld must be disclosed in the consent process and form. (i.e. standard-of-care drug, different interventional procedure, no procedure or treatment, palliative care, other research studies).**

Alternative Treatments for SUDSs include in-person individual and group forms of psychotherapy as well as Alcoholics Anonymous and Narcotics Anonymous.

All alternative options will be provided if she/he/they wishes to engage in an alternative treatment rather than the proposed study. However, given that previous Woebot study results are promising, the proposed line of treatments would appear to be appropriate and acceptable interventions for SUDs.

No standard treatment is being withheld.

- f) Will it be possible to continue the more (most) appropriate therapy for the participant(s) after the conclusion of the study?**

Yes

- g) Study Endpoint. What are the guidelines or end points by which you can evaluate the different treatments (i.e. study drug, device, procedure) during the study? If one proves to be clearly more effective than another (or others) during the course of a study, will the study be terminated before the projected total participant population has been enrolled? When will the study end if no important differences are detected?**

The endpoint will be the follow-up 30 days after end-of-treatment. This will end their study participation and study staff will do analysis.

**3. Background**

- a) Describe past experimental and/or clinical findings leading to the formulation of the study.**

Woebot's app-based platform and user-centered design philosophy makes

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

it an optimal modality for SUDs treatment delivery; it offers immediate, evidence-based tailored support in the patient's peak moment of craving. An RCT demonstrated that Woebot had statistically and clinically significant reductions in depression compared to a control group, along with best in class app-engagement rates (mean=12 interactions in 14 days). Woebot does not currently offer a SUDs program, although 63% of current users expressed interest in said content. Woebot's current, substantial reach as a consumer app, preliminary data indicating its high user engagement plus efficacy to treat a psychological condition, posies it as an ideal platform for a SUDs-focused, tailored, and immediately scalable digital therapeutic.

In the Woebot-SUDs phase 1 (pilot) study, there are 2,450+ screening attempts, indicating interest in a digital therapeutic CA on substance use both nationally and internationally. 260 were screened out solely for not residing in the U.S. W-SUDs was feasible to deliver, engaging, and acceptable; and associated with significant improvements in substance use, confidence, cravings, depression, and anxiety. Study attrition was high (50%). Future research will evaluate W-SUDs in a randomized controlled trial with a more diverse sample and with use of greater strategies for study retention.

W-C19 study: COVID-19 offered a unique opportunity for research to consider outbreak levels and policies in our analyses, and the potential for differential effects of a treatment for reducing substance use problems during an infectious disease outbreak. There were 2468+ screening attempts, and 180 participants randomized to a condition. Follow up retention rates have fared better than phase 1. Final retention rate for 4-week assessments is at 79.4% (143/180). EOT retention rate is 84.4% (152/180). Experiencing worsened mental health symptoms during COVID-19 was associated with more substance use problems and depression and anxiety symptoms. Pandemic disruptions may exacerbate preexisting substance use problems.

W-SUDs Pilot for the phase II RCT (IRB 62053): Preliminary data from this study shows that there are feasibility issues with the study including time demand on personnel, complications introduced with the Adobe Sign process (multiple emails to each participant, difficulty with the secure email process, varying delays between screening to consent to baseline survey), MINI interviewing scheduling challenges, and delays between baseline completion and randomization. Based on recruitment data so far, over 1574 screening attempts were made (responses at 0% do not get recorded in Qualtrics), with 128 respondents passing the screening. Of those that have passed, 23 (18% of the 128) have signed informed consent, and 18 have completed the baseline survey. 1 respondent was removed due to no use of substances in the past 30 days. 12 (71% of the 17 completing baseline survey) have completed the MINI interview.

The W-SUDs phase II study will evaluate the efficacy of W-SUDs in a large scale RCT relative to an education-only control condition, where there is no active treatment. To diversify the sample, we will utilize Qualtrics panels and set quotas. We'll utilize retention strategies in the W-C19 study to improve retention.

**b) Describe any animal experimentation and findings leading to the formulation of the study.**

N/A

**4. Radioisotopes or Radiation Machines**

**a) List all standard of care procedures using ionizing radiation (radiation dose received by a subject that is considered part of their normal medical care). List all research procedures using ionizing radiation (procedures performed due to participation in this study that is not considered part of their normal medical care). List each potential procedure in the sequence that it would normally occur during the**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**entire study. More Info**

Identify Week/Month of study	Name of Exam	Identify if SOC or Research
------------------------------	--------------	-----------------------------

**b) For research radioisotope projects, provide the following radiation-related information:**

**Identify the radionuclide(s) and chemical form(s).**

**For the typical subject, provide the total number of times the radioisotope and activity will be administered (mCi) and the route of administration.**

**If not FDA approved provide dosimetry information and reference the source documents (package insert, MIRD calculation, peer reviewed literature).**

**c) For research radiation machine projects, provide the following diagnostic procedures:**

**For well-established radiographic procedures describe the exam.**

**For the typical subject, identify the total number of times each will be performed on a single research subject.**

**For each radiographic procedure, provide the setup and technique sufficient to permit research subject dose modeling. The chief technologist can usually provide this information.**

**For radiographic procedures not well-established, provide FDA status of the machine, and information sufficient to permit research subject dose modeling.**

**d) For research radiation machine projects, provide the following therapeutic procedures:**

**For a well-established therapeutic procedure, identify the area treated, dose per fraction and number of fractions. State whether the therapeutic procedure is being performed as a normal part of clinical management for the research participants's medical condition or whether it is being performed because the research participant is participating in this project.**

**For a therapeutic procedure that is not well-established, provide FDA status of the machine, basis for dosimetry, area treated, dose per fraction and number of fractions.**

**5. Devices**

**a) Please list in the table below all Investigational Devices (including Commercial Devices used off-label) to be used on participants.**

**5.1 Device Name : Woebot**

**Describe the device to be used.**

**Woebot, a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**(SUD) treatment delivery; it offers immediate, evidence-based tailored support in the patient's peak moment of craving.**

**Manufacturer :** Woebot Labs

**Risk :** Non-significant

Y I confirm the above are true.

**Rationale for the device being non-significant risk:**

The research aims to enroll a low-treatment seeking population, and employ randomization to two low-risk interventions, we do not envisage that participation in the study will be associated with elevated risk.

**Sponsor of Project**

**Indicate who is responsible for submitting safety reports to the FDA:**

Y The sponsor is the device manufacturer.

**Ordering, Storage and Control**

**To prevent the device being used by a person other than the investigator, and in someone other than a research participant: Confirm that the device will be handled according to the SHC/LPCH policy for Investigational New Devices or as appropriate. If no, please provide an explanation. :**

Y Confirm?

- b) Please list in the table below all IDE Exempt Devices (Commercial Device used according to label, Investigational In Vitro Device or Assay, or Consumer Preference/Modifications/Combinations of Approved Devices) to be used on participants.**

**6. Drugs, Reagents, or Chemicals and Devices**

- a) Please list in the table below all investigational drugs, reagents or chemicals to be administered to participants.**
- b) Please list in the table below all commercial drugs, reagents or chemicals to be administered to participants.**

**7. Medical Equipment for Human Subjects and Laboratory Animals**

**If medical equipment used for human patients/participants is also used on animals, describe such equipment and disinfection procedures.**

N/A

**8. Participant Population**

- a) State the following: (i) the number of participants expected to be enrolled at Stanford-affiliated site(s);**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**(ii) the total number of participants expected to enroll at all sites; (iii) the type of participants (i.e. students, patients with certain cancer, patients with certain cardiac condition) and the reasons for using such participants.**

N=400 (nationally) will be invited to participate in this study and entered into the study on a rolling basis. Inclusion criteria include: all genders aged 18-65 years, meet CAGEAID score of 2+ (WSUDs is designed for substance use); access to the apps on smartphone, be available and committed to engage with app and complete assessments, be willing to provide working email address (to distribute incentives), working telephone number (for interview portion and follow ups), and be literate in English (as educational materials and W-SUDs conversational and video materials will be in English). Exclusion criteria include: pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population), history of severe drug/alcohol use, opioid misuse without medication-assisted treatment, and suicide attempt or opioid overdose within the past year.

**b) State the age range, gender, and ethnic background of the participant population being recruited.**

Recruitment efforts will seek to enroll a demographically diverse sample age 18-65. Substance disorders are prevalent in individuals of all genders, therefore all genders will be recruited as participants in the proposed study.

**c) State the number and rationale for involvement of potentially vulnerable subjects in the study (including children, pregnant women, economically and educationally disadvantaged, decisionally impaired, homeless people, employees and students). Specify the measures being taken to minimize the risks and the chance of harm to the potentially vulnerable subjects and the additional safeguards that have been included in the protocol to protect their rights and welfare.**

These populations are not being targeted but are also not excluded from the study. Exception: Pregnant women and children will be screened out.

**d) If women, minorities, or children are not included, a clear compelling rationale must be provided (e.g., disease does not occur in children, drug or device would interfere with normal growth and development, etc.).**

Exclusion of Pregnant Women: Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population). Exclusion of Children. The proposed study will include individuals between 18-65 years of age. Persons younger than 18 will not be included in the study, as the proposed substance disorder treatments were not designed for nor tested among youth and the characterization of SUD in youth differs in meaningful ways from that in adults. Given the small sample sizes for this pilot and that Woebot has not yet been tested among youth, the proposed research is focused on those aged 18 and older.

**e) State the number, if any, of participants who are laboratory personnel, employees, and/or students. They should render the same written informed consent. If payment is allowed, they should also receive it. Please see Stanford University policy.**

0

**f) State the number, if any, of participants who are healthy volunteers. Provide rationale for the inclusion of healthy volunteers in this study. Specify any risks to which participants may possibly be exposed. Specify the measures being taken to minimize the risks and the chance of harm to the volunteers and the additional safeguards that have been included in the protocol to protect their rights and welfare.**

0 healthy volunteers. 268 volunteers for the main trial will have endorsed a substance use concern for problematic use and screened out if pregnant during recruitment. Other than these health implications, participants will otherwise be healthy volunteers and will not be exposed to health risks through their participation.

**g) How will you identify and recruit potential participants about the research study? (E.g., by: Honest Broker or other <https://researchcompliance.stanford.edu/participantengagement> Research Participation services; chart review; treating physician; ads). All final or revised recruitment materials, flyers, etc. must be submitted to the IRB for review and approval before use. You may not**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**contact potential participants prior to IRB approval. See Advertisements: Appropriate Language for Recruitment Material.**

Recruitment: For this study, Woebot Labs' may post study advertisements and recruit via their already active internet channels including Twitter (over 2,000 followers), LinkedIn (over 400 followers), and Facebook (over 16,500 followers). To supplement recruitment, Woebot Labs' may post on Craigslist, Nextdoor, Google Ads, and on Reddit through relevant subreddits with written permission from the subreddits' moderators. Woebot may email clinics. Woebot may also post physical flyers and the Stanford team may post on the Stanford Staffers listserv. The Stanford team may recruit from the WELL cohort via newsletter, with permission. Stanford staff may post in other listservs with permission. The Stanford team may recruit participants from other studies who have indicated interest in other studies. The team may use Qualtrics panels, ResearchMatch (online health research tool funded by NIH to match volunteers with studies), the Stanford COVID-19 directory to recruit, and other third party recruitment vendors (e.g. Splash Clinical, Map & Story, Clara Health). Woebot exchanges an average of 1-2 million messages per week with its users. Woebot users have indicated interest in substance use content. Specifically, 63% of current users (surveyed in July 2018) reported interest in content related to substance use. In regards to their specific substance use behaviors over the previous month, 22% of users reported having 5 or more alcoholic drinks in a row within a couple of hours (i.e., binge use), and 5% endorsed using non-prescription drugs. Woebot Labs has used these channels for previous research participation invitations with success.

Minor editing changes may be made to recruitment materials to enhance clarity.

Participants will be asked for their age during the screener. If ineligible, they will be not be able to participate in the study. We will ask for date of birth in the questionnaire after the signed consent to confirm that the participant is not underage. This is standard best practice for use of the program and for other online research studies.

**h) Inclusion and Exclusion Criteria.**

**Identify inclusion criteria.**

Inclusion Criteria:

Eligible participants for this trial must:

1. Have a smartphone
2. Endorse a substance use concern
3. Be between 18 and 65 years of age
4. Be available and committed to engage with the Woebot app
5. Be literate in English.(This is required for inclusion because all materials will be in English).

**Identify exclusion criteria.**

Exclusion Criteria:

1. Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population)
2. Suicide attempt within the past year (12 months)
3. Symptoms of severe drug/alcohol history: History of delirium tremens; Experiencing hypertension, drenching sweats, seizures or confusion after stopping alcohol or drugs; Liver trouble (cirrhosis or hepatitis); Convulsions or GI bleeding due to drug/alcohol use
4. Opioid overdose within the past year (12 months)
5. Opioid misuse without medication-assisted treatment
6. Not residing in the U.S.
7. Ever used Woebot

**i) Describe your screening procedures, including how qualifying laboratory values will be obtained. If you are collecting personal health information prior to enrollment (e.g., telephone screening), please request a waiver of authorization for recruitment (in section 15).**

**Screening**

There will be a brief internet delivered (via Qualtrics or REDCap) screener that will ascertain if individuals who express interest in participating in the study meet inclusion criteria. The screener-battery will include the Drug Abuse Screening Test (DAST-10), CAGE Questions Adapted to Include Drug Use (CAGE-AID),

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Michigan Alcohol Screening Test (MAST), Psychosis Screening Questionnaire (PSQ), and a few relevant demographic questions (i.e., age, pregnancy status, suicide or overdose within the past year). Those who do not meet criteria will be welcomed to begin using the generic (non-SUD focused) Woebot and the website without restriction but will not be enrolled into the study. In addition, additional substance treatment resources will be provided.

- j) Describe how you will be cognizant of other protocols in which participants might be enrolled. Please explain if participants will be enrolled in more than one study.**  
 Consent form will ask whether the participant is currently enrolled in any additional studies.
- k) Payment/reimbursement. Explain the amount and schedule of payment or reimbursement, if any, that will be paid for participation in the study. Substantiate that proposed payments are reasonable and commensurate with the expected contributions of participants and that they do not constitute undue pressure on participants to volunteer for the research study. Include provisions for prorating payment. See payment considerations**  
 Phase II funding approved. For each of the 400 participants: \$25 for completing the baseline survey; \$25 for 4-week survey completion; \$25 for EOT (8-week) assessment completion; \$25 for the 12-week (30 days post EOT) assessment completion. Total amount possible per participant is \$100.

- l) Costs. Please explain any costs that will be charged to the participant.**

There will be no cost to participants.

- m) Estimate the probable duration of the entire study. Also estimate the total time per participant for: (i) screening of participant; (ii) active participation in study; (iii) analysis of participant data.**  
 Total duration for the research team is estimated to be 11 months. Content development is ready. Recruitment for about 5 months. Participation in the study is estimated to be 3 months. Estimated time for screening is around 5 minutes; Each survey estimated to be 15-30min. Study intervention is 8-weeks/2 months. Active participation is 3 months with follow up surveys at the 4- week, 8- week, and 12-week marks.  
 Data analysis is estimated to be 3 months.

## 9. Risks

- a) For the following categories include a scientific estimate of the frequency, severity, and reversibility of potential risks. Wherever possible, include statistical incidence of complications and the mortality rate of proposed procedures. Where there has been insufficient time to accumulate significant data on risk, a statement to this effect should be included. (In describing these risks in the consent form to the participant it is helpful to use comparisons which are meaningful to persons unfamiliar with medical terminology.)**

**The risks of the Investigational devices.**

N/A

**The risks of the Investigational drugs. Information about risks can often be found in the Investigator's brochure.**

N/A

**The risks of the Commercially available drugs, reagents or chemicals. Information about risks can often be found in the package insert.**

N/A

**The risks of the Procedures to be performed. Include all investigational, non-investigational and non-invasive procedures (e.g., surgery, blood draws, treadmill tests).**

N/A

**The risks of the Radioisotopes/radiation-producing machines (e.g., X-rays, CT scans, fluoroscopy) and**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**associated risks.**

N/A

**The risks of the Physical well-being.**

N/A

**The risks of the Psychological well-being.**

Potential Upset due to Survey Questions: Foreseeable risks to subjects include the possibility that some assessment questions and/or treatment procedures may be upsetting to subjects. Experience at Stanford with similar populations has indicated that the risk of emotional upset during the assessments is low and if it occurred, the upset would likely not be serious in nature and temporary. Such risks will be minimized by the thoughtful selection of questionnaires. Potential participants will also be informed that they may drop out of the study at any time and if requested, appropriate treatment referrals would then be given.

Possible risks of Woebot: Woebot is not intended to replace standard of care and should not be used in place of standard treatment.

Neither of the intervention groups are crisis services.

**The risks of the Economic well-being.**

N/A

**The risks of the Social well-being.**

Potential loss of confidentiality.

**Overall evaluation of Risk.**

Low - innocuous procedures such as phlebotomy, urine or stool collection, no therapeutic agent, or safe therapeutic agent such as the use of an FDA approved drug or device.

- b) If you are conducting international research, describe the qualifications/preparations that enable you to both estimate and minimize risks to participants. Provide an explanation as to why the research must be completed at this location and complete the [LINKFORINTERNATIONALREASEARCHFORM] International Research Form. If not applicable, enter N/A.**

N/A

- c) Describe the planned procedures for protecting against and minimizing all potential risks. Include the means for monitoring to detect hazards to the participant (and/or to a potential fetus if applicable). Include steps to minimize risks to the confidentiality of identifiable information.**

Given that the research aims to enroll a low-treatment seeking population, we do not envisage that participation in the study will be associated with elevated risk. We are not assessing suicidal ideation in our questionnaires. During the eligibility screener, those who have had a suicide attempt within the past year will be excluded from the study. It is not feasible to confirm the responses by participants to the questionnaires in real time. However, some risk is always present in studies that involve human participants. Such risk may include the following:

1. Data Protection and Privacy: All study data are gathered on a HIPAA compliant web platform that resides behind Stanford security firewalls and has been tried and tested by the University for several years, thus actual risk from data breach for study data is low. All assessments, including the screening, four assessment batteries, and mediator assessment will be administered via a HIPAA compliant survey administration tool commonly used by Stanford University in its clinical trials (Qualtrics or REDCap). Given the high data protection safeguards embedded within Qualtrics or REDCap, there is little risk to the subject associated in regards to their privacy and/or confidentiality.

Research material obtained from human subjects will involve behavioral and psychological assessments including self-report questionnaires. All data will be obtained specifically for purposes of this research project. Data that is obtained from the Qualtrics or REDCap assessments will be stored and protected within

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Qualtrics or REDCap. Data that is obtained via Woebot will be encrypted and stored on Amazon Web Services (AWS); Woebot Labs data gathering and storage procedures are compliant with both the Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR) compliant. Only members of the research team (PI, Co-PIs, biostatistician, research assistant) will have access to the data.

2. Potential Upset due to Survey Questions: Foreseeable risks to subjects include the possibility that some assessment questions and/or treatment procedures may be upsetting to subjects. Experience at Stanford with similar populations has indicated that the risk of emotional upset during the assessments is low and if it occurred, the upset would likely not be serious in nature and temporary. Such risks will be minimized by the thoughtful selection of questionnaires. Potential participants will also be informed that they may drop out of the study at any time and if requested, appropriate treatment referrals would then be given.

3. Risk of treatment avoidance due to engagement with either of the randomized interventions. In both interventions it is explicitly stated that the service should not be used in place of traditional treatment. In the case of the W-SUDs intervention, Woebot is designed to hold individuals accountable for pursuing additional options in conditions of unchanged symptoms for a prolonged amount of time (4 weeks). In addition, Woebot will invite the user to consider what seeking additional services would look like.

4. Risk of suicide: Woebot informs the participant that it is not designed for crisis service. Additionally, Woebot detects crisis language (e.g. "want to kill") and asks to confirm it with the user. If the user confirms, Woebot automatically, in real-time offers resources (9-1-1, suicide crisis hotlines, referral to ER). Woebot's crisis detectors flags around 200 possible harm to self phrases, including about 10 misspellings and 5 slang phrases. Woebot's data indicate that users do not use Woebot for crisis management; about 6.3% trigger the safety net protocol, of which 27% confirm that it is indeed a crisis (i.e., for a true crisis rate of 1.7%). Woebot's algorithm is over-sensitive, designed to over-detect, rather than under-detect to make sure that cases are not missed. Woebot staff periodically check the data for true/false positive rates. Additionally, if anyone is developing or indicating serious thoughts about suicide or harming themselves, it is best practice to call 9-1-1 and/or go to the nearest ER.

**d) Explain the point at which the experiment will terminate. If appropriate, include the standards for the termination of the participation of the individual participant Also discuss plans for ensuring necessary medical or professional intervention in the event of adverse effects to the participants.**

The study will terminate once the 3-month period with all 400 participants has been completed and the analyses run and submitted for publication.

Participants can refuse to participate at any time.

When we learn of a participant's adverse event, the team will report the adverse event and may follow up with the participant for additional information. Resources will be offered. The EOT and 12-week surveys includes questions that assess for SAEs. More details about adverse events are in section e.

**e) Data Safety and Monitoring Plan (DSMP). See guidance on Data Safety and Monitoring.**

**A Data and Safety Monitoring Plan (DSMP) is required for studies that present Medium or High risk to participants. (See Overall Evaluation of Risk above). If Low Risk, a DSMP may not be necessary. Multi-site Phase III clinical trials funded by NIH require the DSM Plan to have a Data Safety Monitoring Board or Committee (DSMC or DSMB). The FDA recommends that all multi-site clinical trials that involve interventions that have potential for greater than minimal risk to study participants also have a DSMB or DSMC.**

**The role of the DSMC or DSMB is to ensure the safety of participants by analyzing pooled data from all sites, and to oversee the validity and integrity of the data. Depending on the degree of risk and the complexity of the protocol, monitoring may be performed by an independent committee, a board (DSMC/DSMB), a sponsor's Data Safety Committee (DSC), a Medical Monitor, a sponsor's safety officer, or by the Protocol Director (PD).**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

### Describe the following:

**What type of data and/or events will be reviewed under the monitoring plan, e.g. adverse events, protocol deviations, aggregate data?**

The Data Safety and Monitoring Plan will include Woebot's standard safety net protocol as well as a Data Safety and Monitoring Board overseen by Stanford University. Woebot's Safety Net Procedures Study informed consent will state that Woebot is not a crisis program designed to address active suicidal ideation or overdose. Woebot also conversationally informs first time users that it is not a crisis service. Our current safety net protocol will be adapted for the proposed study. Woebot's crisis detectors flags around 200 possible harm to self phrases, including about 10 misspellings and 5 slang phrases. Woebot detects crisis language (e.g. "want to kill") and asks to confirm it with the user. If the user confirms, Woebot offers resources (9-1-1, suicide crisis hotlines), carefully curated with expert consultation. Our data indicate that users do not use Woebot for crisis management; about 6.3% trigger the safety net protocol, with 27% confirming that it is indeed a crisis when Woebot asks to confirm (i.e., our true positive rate). To make sure that we do not miss any cases, we over detect, rather than under detect. In addition, we periodically check the data for true/false positive rates. Adverse Events We do not anticipate that the use of the interventions will increase risk as outlined above. In addition, there is a limited capacity to detect adverse events (such as overdose, suicide attempt or hospitalization related to substance use or other) unless explicitly voluntarily reported by the participant. In the case Stanford University and / or Woebot Labs becomes aware of an adverse event, the appropriate protocol, approved by the DSMB and Stanford University's Institutional Review Board, will be immediately implemented. This includes immediate notification of the IRB, DSMB, and NIH, and an immediate convening of the DSMB to discuss requisite follow-up steps.

**Identify who will be responsible for Data and Safety Monitoring for this study, e.g. Stanford Cancer Institute DSMC, an independent monitoring committee, the sponsor, Stanford investigators independent of the study, the PD, or other person(s).**

To ensure the data protection and safety of research participants, Stanford University will serve as the Data Coordinating Center for the study under the coordination of Drs. Biaocchi and Prochaska. They will convene a group of three to serve as an oversight board with professional expertise in the area of the study. Dr. Prochaska is an expert in the field of addiction and substance use, and Dr. Biaocchi has experience in managing data protections in the context of randomized clinical trials.

**Provide the scope and composition of the monitoring board, committee, or safety monitor, e.g., information about each member's relevant experience or area of expertise. If the Monitor is the Stanford Cancer Center DSMC or the PD, enter N/A.**

DSMB's specific goals: • Review new or modifications to existing risk management protocols • Review procedures for maintaining confidentiality, data collection, management, and analyses • Review progress towards meeting enrollment goals • Recommend continuation, discontinuation, modification, or termination of a study based on emerging data (from the study and from the literature) and evaluation of risk/benefit ratios • Conduct annual reviews to determine whether patient safety has been adequately safeguarded • Review progress reports

**Confirm that you will report Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs), or Unanticipated Problems (UPs) to the person or committee monitoring the study in accordance with Sponsor requirements and FDA regulations.**

Yes.

**If applicable, how frequently will the Monitoring Committee meet? Will the Monitoring Committee provide written recommendations about continuing the study to the Sponsor and IRB?**

Dr. Prochaska will coordinate the meetings by assisting in setting the agenda and ensuring that the necessary materials are provided for each meeting. The initial meeting of the Board will take place during the first three months of the study, i.e., before entry into the second Phase of the research, to allow for the consideration of the protocol from the viewpoint of data safety and participant

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

confidentiality. Subsequent meetings will be held at 6-month intervals, with the possibility for either an interim meeting or telephone conversation conference call should the necessity arise. At the first meeting, Dr. Prochaska will brief the board on the study design and procedures. The Board will then provide feedback on the data that they will wish to review at their subsequent meetings.

**Specify triggers or stopping rules that will dictate when the study will end, or when some action is required. If you specified this in Section 2g [Study Endpoints], earlier in this application enter 'See 2g'.**

Endpoints will be indicated by the cessation of W-SUDs and educational intervention delivery at 8-weeks, the 12-week mark for WSUDs group (content will no longer be accessible), data analysis and interpretation, refinement of W-SUDs, and the end of the 3 month period (ending mark of the study).

**Indicate to whom the data and safety monitoring person, board, or committee will disseminate the outcome of the review(s), e.g., to the IRB, the study sponsor, the investigator, or other officials, as appropriate.**

The proposed study has a dissemination plan that encapsulates two important arenas: 1) ClinicalTrials.gov compliance and 2) Dissemination. ClinicalTrials.gov Compliance If the proposal is successfully awarded, the applicant will ensure that the trial's registration and results reporting procedures are thoroughly managed. The trial will be registered promptly upon receipt of the award and before the recruitment of human subjects. All informed consent documents will include specific and thorough statements referring to the posting on ClinicalTrials.gov. At the conclusion of the study and following analysis of the results, results will be reported as well, in compliance with the ClinicalTrials.gov procedures. Woebot Labs has a protocol in place outlining the importance and details of ensuring the ClinicalTrials.gov procedures are up to date. Dissemination of Research Both Stanford University and Woebot Labs will facilitate with the dissemination of research. They will collaborate on manuscript preparation and submission, as well as abstract submission and presentations at national and international scientific and technology-oriented conferences.

**Select One:**

- The Protocol Director will be the only monitoring entity for this study.  
 This protocol will utilize a board, committee, or safety monitor as identified in question #2 above.

**10. Benefits**

- a) Describe the potential benefit(s) to be gained by the participants or by the acquisition of important knowledge which may benefit future participants, etc.**

When evaluating the risks and benefits of the proposed study, it is believed that risks are relatively minimal when compared to the potential therapeutic benefits that subjects are likely to receive. The benefits of receiving W-SUDs include potentially reducing substance abuse, acquiring practical psychotherapeutic skills (from cognitive behavioral therapy, motivational interviewing, dialectical behavior therapy, and mindfulness), and receiving psychoeducation about substance abuse. Participants who reduce substance abuse may derive additional benefits should reduction in substance abuse be associated with other psychological improvements such as interpersonal or occupational functioning. Study of the effectiveness of this intervention will also benefit society more generally by providing data on the efficacy, utility, and cost-benefits of a W-SUDs, the first SUDs-focused digital therapeutic delivered by an artificial intelligence (AI)-powered conversational agent.

The study allows the opportunity to expand understanding of W-SUDs' performance among this population and will offer those in the WSUDs group immediate access to a digital therapeutic in a resource constrained, socially distanced healthcare ecosystem to an already vulnerable and underserved population, who are likely faced with readily growing psychological challenges.

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

## 11. Privacy and Confidentiality

### Privacy Protections

- a) Describe how the conditions under which interactions will occur are adequate to protect the privacy interests of participants (e.g., privacy of physical setting for interviews or data collection, protections for follow-up interactions such as telephone, email and mail communications).**

All assessments, including the screening and the four assessment batteries, will be administered via a HIPAA compliant survey administration tool commonly used by Stanford University in its clinical trials (Qualtrics or REDCap). Given the high data protection safeguards embedded within Qualtrics and REDCap, there is little risk to the subject associated in regards to their privacy and/or confidentiality.

Informed consent will utilize Stanford's Adobe Sign platform and procedures for part 11 compliance.

Research material obtained from human subjects will involve behavioral and psychological assessments (including self-report questionnaires). All data will be obtained specifically for purposes of this research project. Data that is obtained from the Qualtrics or REDCap assessments will be stored and protected within Qualtrics or REDCap. Data that is obtained via Woebot will be encrypted and stored on Amazon Web Services (AWS); Woebot Labs data gathering and storage procedures are compliant with both the Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR) compliant. Only members of the research team (PI, Co-PIs, biostatistician, research assistant) will have access to the data.

### Confidentiality Protections

- b) Specify PHI (Protected Health Information). PHI is health information linked to HIPAA identifiers (see above). List BOTH health information AND HIPAA identifiers. If you are using STARR, use the Data Privacy Attestation to ensure that your request will match your IRB-approved protocol. Be consistent with information entered in section 15a.**

Individual names, email addresses, mailing addresses, phone numbers, dates of birth, demographic information (gender, biological sex, race/ethnicity, disability status), IP addresses, geo location, survey, drug use.

### Drug Use Psychopathology

1. The Drug Abuse Screening Test 10 (DAST-10), a brief, 10-item self-report measure adapted from the 28-item DAST, assesses consequences related to drug abuse, excluding alcohol and tobacco. A score of 3 or higher indicates significant problems related to drug abuse. The DAST-10 demonstrated discriminant validity between individuals (i) with lifetime drug use disorders and those without and (ii) who are current abusers and those who are former abusers. It also has moderate level of test-retest and reliability as well as sensitivity and specificity.
2. The Drug Abstinence Self-Efficacy Scale (DASE) is a 12-item self-report scale, reflecting Bandura's (1986) cognitive-behavioral self-efficacy theory, and is a shortened version of the original 20-item scale. The 20-item scale has shown to be a reliable and valid measure of self-efficacy for drug use. The scale will be adapted to refer to use of both drugs and alcohol, by including that language in the item stem.

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

3. The CAGE Adapted to Include Drug USE (CAGE-AID) was developed by the John Hopkins Dept of Medicine. It's a brief instrument to measure problematic drug use. The CAGE-AID is designed to be an easy yet effective way for primary care providers to determine if substance abuse exists and needs to be addressed.

4. The Michigan Alcohol Screening Test (MAST), revised is a 22 question instrument to measure problematic alcohol use. One of the most widely used measures for assessing alcohol abuse, the MAST is a questionnaire designed to provide a rapid and effective screening for lifetime alcohol-related problems and alcoholism. The MAST has been productively used in a variety of settings with varied populations.

5. The Short Inventory of Problems- Alcohol and Drugs (SIP-AD) is a clinically tested 15-item measure developed by NIH funded research that assesses severity of problematic drinking and drug usage.

6. The Quick Drinking Screen (QDS) by Sobell & Sobell (2003), is a brief and reliable measure of drinking. Compared with the Timeline Followback (TLFB), the QDS collected similar aggregate drinking data for four drinking variables in a clinical sample of alcohol abusers.

#### General Psychopathology

9. The Patient Health Questionnaire (PHQ-8) is a brief 8-item scale used to determine the severity of depression in medical populations. The PHQ-8 has high reliability across populations.

10. The Generalized Anxiety Disorder (GAD-7) is a brief self-report scale that identifies the degree to which an individual may have generalized anxiety disorder. This scale has good internal consistency, convergent validity with depression, stress, and anxiety, and is a valid and efficient tool for GAD screening in clinical and general populations.

#### Employee Health

11. The Stanford Presenteeism Scale is (SPS-6) a six item measure derived from a 34 item measure of workforce productivity impacted by health status. The 6-item scale has excellent psychometric properties and has been validated.

12. The CAIR Pandemic Impact Questionnaire (C-PIQ) and the International COVID-19 Awareness and Evaluation Study questions were developed for measuring the impact of COVID-19. These include questions about COVID-19 in relation to their health, work, and lifestyle changes.

- c) You are required to comply with University Policy that states that ALL electronic devices: computers (laptops and desktops; OFFICE or HOME); smart phones; tablets; external hard disks, USB drives, etc. that may hold identifiable participant data will be password protected, backed up, and encrypted. See <http://med.stanford.edu/datasecurity/> for more information on the Data Security Policy and links to encrypt your devices.

Provide any additional information on ALL data security measures you are taking. You must use secure databases such as <https://researchcompliance.stanford.edu/panels/hs/redcap> RedCap. If you are unsure of the security of the system, check with your Department IT representative. Please see <http://med.stanford.edu/irt/security/> for more information on IRT Information Security Services and [http://www.stanford.edu/group/security/securecomputing/mobile\\_devices.html](http://www.stanford.edu/group/security/securecomputing/mobile_devices.html) for more information for securing mobile computing devices. Additionally, any PHI data on paper must be secured in an locked environment.

By checking this box, You affirm the aforementioned. Y

All assessments, including the screening and three assessment batteries, will be administered via a HIPAA compliant survey administration tool commonly used by Stanford University in its clinical trials (Qualtrics

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

or REDCap). Given the high data protection safeguards embedded within Qualtrics, there is little risk to the subject associated in regards to their privacy and/or confidentiality.

Research material obtained from human subjects will involve behavioral and psychological assessments including self-report questionnaires. All data will be obtained specifically for purposes of this research project. Data that is obtained from the Qualtrics or REDCap assessments will be stored and protected within Qualtrics or REDCap, and on Stanford Medicine Box. Data that is obtained via Woebot will be encrypted and stored on Amazon Web Services (AWS); Woebot Labs data gathering and storage procedures are compliant with both the Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR) compliant. Only members of the research team (PI, Co-PIs, biostatistician, research assistant) will have access to the data.

The Stanford research team will use Stanford encrypted, password protected, and backed up electronic devices (laptops, mobile devices) for this project.

- d) Describe how data or specimens will be labeled (e.g. name, medical record number, study number, linked coding system) or de-identified. If you are de-identifying data or specimens, who will be responsible for the de-identification? If x-rays or other digital images are used, explain how and by whom the images will be de-identified.**

Each participant will be assigned a unique study ID number that will take the place of any identifying information. Surveys will be done online with individual survey URLs matched to study ID provided to participants. All data therefore will be coded for the large dataset.

No names will be attached to surveys or biomarker tests. Study staff is responsible for the coding.

Woebot user data provided to Stanford will be de-identified and linked via study ID to the study assessments we collect via RedCap or Qualtrics and the data will not be shared outside of the Woebot and Stanford teams.

- e) Indicate who will have access to the data or specimens (e.g., research team, sponsors, consultants) and describe levels of access control (e.g., restricted access for certain persons or groups, access to linked data or specimens).**

The PD and co-investigator and the research team will have access to the study data. All data will be locked or password-protected or both.

- f) If data or specimens will be coded, describe the method in which they will be coded so that study participants' identities cannot be readily ascertained from the code.**

Each participant will be assigned a unique participant ID number, starting with 001 through 1000, to code data.

- g) If data or specimens will be coded, indicate who will maintain the key to the code and describe how it will be protected against unauthorized access.**

The codes of names and ID numbers will be accessed by the research team only, stored securely in Qualtrics or REDCap, and/or a password protected file.

- h) If you will be sharing data with others, describe how data will be transferred (e.g., courier, mail) or transmitted (e.g., file transfer software, file sharing, email). If transmitted via electronic networks, describe how you will secure the data while in transit. See <http://www.stanford.edu/group/security/securecomputing/> <http://www.stanford.edu/group/security/securecomputing/>. Additionally, if you will be using or sharing PHI see <https://uit.stanford.edu/security/hipaa> <https://uit.stanford.edu/security/hipaa>.**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Coded data may be sent by secure email settings provided by Stanford, or through Stanford Medicine Box.

Woebot user data provided to Stanford will be coded and linked via study ID to the study assessments we collect via RedCap or Qualtrics and the data will not be shared outside of the Woebot and Stanford teams.

- i) How will you educate research staff to ensure they take appropriate measures to protect the privacy of participants and the confidentiality of data or specimens collected (e.g. conscious of oral and written communications, conducting insurance billing, and maintaining paper and electronic data)?**

The research staff will all be HIPAA and CITI trained and compliant and supervised by Dr. Prochaska.

## 12. Potential Conflict of Interest

Investigators are required to disclose any financial interests that "<https://researchcompliance.stanford.edu/eprotocol-coi>" target="\_blank" reasonably appear to be related/li to this protocol.

### Financial Interest Tasks

Investigators	Role	Potential COI?	Date Financial Interest Answered	Date OPACS Disclosure Submitted	COI Review Determination
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

## 13. Consent Background

### 13.1 Consent

#### Screening Consent

Check if VA related

- a) Describe the informed consent process. Include the following.
- Who is obtaining consent? (The person obtaining consent must be knowledgeable about the study.)
  - When and where will consent be obtained?
  - How much time will be devoted to consent discussion?
  - Will these periods provide sufficient opportunity for the participant to consider whether or not to participate and sign the written consent?
  - What steps are you taking to minimize the possibility of coercion and undue influence?
  - If consent relates to children and if you have a reason for only one parent signing, provide that rationale for IRB consideration.

(i) Study staff will be obtaining the consent via online questionnaire (Qualtrics or REDCap). (ii) This

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

consent will be at the beginning of the screening questionnaire (Qualtrics or REDCap). Since consent is obtained online, it can be obtained at any location of the participants choosing. (ii) There is no time limit- each respondent can take much time as they want to read through the consent. Reading consent is anticipated to not take more than five minutes. (iv) Since consent is obtained online, the participant may take as much time as they wish to consider whether or not to participate and proceed with the screener. (v) No incentive or form of coercion is present for the screening process. The study is voluntary; Participants are informed that they can withdraw or choose not to participate at any time. There is no payment for going through the screener. (vi) N/A.

- b) What is the Procedure to assess understanding of the information contained in the consent? How will the information be provided to participants if they do not understand English or if they have a hearing impairment? See HRPP Chapter12.2 for guidance.**

We are not recruiting participants who cannot understand English.

- c) What steps are you taking to determine that potential participants are competent to participate in the decision-making process? If your study may enroll adults who are unable to consent, describe (i) how you will assess the capacity to consent, (ii) what provisions will be taken if the participant regains the capacity to consent,(iii) who will be used as a legally authorized representative, and (iv) what provisions will be made for the assent of the participant.**

Participants will be reading the consent form before beginning the screener. Participants must be English literate to participate as the questionnaires, consent forms, and Woebot app are only available in English. The participant will have to select "Agree" to participate in the study. Contact information is also provided during consent for the participant to use if they have questions about the study.

### 13. 2 Alteration of Consent

### Phase 2 ICF - Alteration of Consent

Check if VA related

- a) Describe the informed consent process. Include the following.**

- i) Who is obtaining consent? (The person obtaining consent must be knowledgeable about the study.)
- ii) When and where will consent be obtained?
- iii) How much time will be devoted to consent discussion?
- iv) Will these periods provide sufficient opportunity for the participant to consider whether or not to participate and sign the written consent?
- v) What steps are you taking to minimize the possibility of coercion and undue influence?
- vi) If consent relates to children and if you have a reason for only one parent signing, provide that rationale for IRB consideration.

(i) Consent will be obtained via Adobe Sign platform. (ii) The online consent can be obtained at anytime and place the potential participant would like. (iii) Potential participants may take as long as they like to read through the consent form. Estimated time is 5min. Contact information is available on the consent form if any questions come up. Potential participants will be informed of what to expect on the survey platform. Informed consent form will be accessed on Adobe Sign. Passwords will be provided via secure email or by phone. The Adobe Sign email template will also include the study team's contact information if any questions come up. Fully signed consent forms will be provided via secure email or as a password protected document in an email. (iv) Yes. (v) Study staff will not be with the potential participant and there will be no possibility of coercion or undue influence. (vi) If under 18 years of age, the respondent is screened out before the consent form appears.

- b) What is the Procedure to assess understanding of the information contained in the consent? How will the information be provided to participants if they do not understand English or if they have a hearing impairment? See HRPP Chapter12.2 for guidance.**

Only English fluent participants will be recruited. The Consent form will be readable and those with a hearing impairment will still be able to access the consent form.

- c) What steps are you taking to determine that potential participants are competent to participate in the decision-making process? If your study may enroll adults who are unable to consent, describe (i) how you will assess the capacity to consent, (ii) what provisions will be taken if the participant regains the capacity to consent,(iii) who will be used as a legally authorized representative, and (iv) what provisions will be made for the assent of the participant.**

The consent form will only be accessible to those who can meet screening criteria. Participation will only include those competent to consent in the low risk study.

**Address the following four regulatory criteria for an alteration of consent and provide protocol-specific justification for each:**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**1) Y The research involves no more than minimal risk to the participants.**

The study is a RCT with group blinding to test whether WSUDs is more effective in reducing problematic substance use than an education only control. The study will involve four questionnaires about physical and mental health, and substance use. Participation information will be coded and stored on compliant platforms (Stanford Medicine Box) and on encrypted, password protected computers. App data is protected with Woebot's security measures.

**2) Y The waiver or alteration will not adversely affect the rights and welfare of the participants.**

Confidentiality and HIPAA practices will still be in place. Data is stored on compliant platforms (e.g. Qualtrics, Stanford Medicine Box) and on encrypted password protected computers.

**3a) Y The research could not practically be carried out with out the requested waiver or alteration.**

**3b) Y For research using identifiable private information or identifiable biospecimens, the research could not practically be carried out without using such information or biospecimens in an identifiable format.**

There will be intervention group blinding to maximize validity and minimize bias. To keep the group blinding effective, the groups are not fully described in the consent form, and full details of the group intervention a participant is randomized to will be provided after randomization. A debrief will be provided to participants after the 12-week assessment period.

**4) Y Whenever appropriate, the participants or legally authorized representatives will be provided with additional pertinent information after participation.**

Participants will be provided with a debrief of group blinding at the end of their study participation. This will be provided by email either be after completion of the final survey or a month after the final survey was due (for those who don't complete the final survey).

**14. Assent Background (less than 18 years of age)**

**15. HIPAA Background**

**15. 1 Waiver of Authorization for waiver of authorization for recruitment  
Recruitment**

**a) Describe the protected health information (PHI) needed to conduct screening or recruitment. PHI is health information linked to HIPAA identifiers. List BOTH health information AND HIPAA identifiers. If you are using STARR, use the Data Privacy Attestation to ensure that your request will match your IRB-approved protocol.**

Those who are interested in screening to participate in the study are asked to sign and print name in the online screening consent as the screening questionnaire involves questions on drug use. PHI collected during screening will include demographics, age, drug use, health history (including mental health), email, IP address (upon entering survey), and name + signature (consent). If a respondent meets eligibility requirements, email and phone number asked for in the screening consent. This is to verify a working email prior to proceeding to next steps (Adobe Sign for informed consent).

**b) Please Answer:**

- Y Do you certify that the use or disclosure of protected health information involves no more than a minimal risk to the privacy of individuals?**
- Y Do you certify that the research could not practically be conducted with out the waiver?**

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

**Y Do you certify that you have adequate written assurances that the protected health information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted?**

**Y Do you certify that the research could not practically be conducted without access to and use of the protected health information?**

**c) Please describe an adequate plan to protect any identifiers from improper use and disclosure.**

The screening survey will be administered via a HIPAA compliant survey administration tool commonly used by Stanford University in its clinical trials (Qualtrics or REDCap). Given the high data protection safeguards embedded within Qualtrics and REDCap, there is little risk to the subject associated in regards to their privacy and/or confidentiality. All data will be obtained specifically for purposes of this research project. Data that is obtained from the Qualtrics or REDCap assessments will be stored and protected within Qualtrics or REDCap, and on Stanford Medicine Box. Only members of the research team (PI Co-PIs, biostatistician, research assistant) will have access to the data. The Stanford research team will use Stanford encrypted, password protected, and backed up electronic devices (laptops, mobile devices) for this project. The research staff will all be HIPAA and CITI trained, compliant, and supervised by Dr. Prochaska.

**d) Please describe an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law.**

Authorization for use and disclosure of the respondent's health information ends on December 31, 2045 or when the research project ends, whichever is earlier. When the authorization expires, the identifiers will manually be destroyed by the study team.

## 16. Attachments

Attachment Name	Attached Date	Attached By	Submitted Date
NIH_NOA_4R44DA048712-02	02/08/2021	achieng	
Resources for Substance Use Treatment 12.9.19	02/08/2021	achieng	
Woebot Scope of Work	02/08/2021	achieng	
Woebot_Security_Risk_Management_Plan_20190812	02/08/2021	achieng	
Woebot_Findings_And_Recommendations (1)	02/08/2021	achieng	
Woebot Privacy Policy	02/08/2021	achieng	
Woebot Data Protection	02/08/2021	achieng	
Woebot_SBIR_Application	02/08/2021	achieng	
Woebot Branching Logic	02/08/2021	achieng	
Directions installing registering Woebot App	02/08/2021	achieng	
Screenshots of Woebot Conversational Pieces	02/08/2021	achieng	

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Woebot Terms of Service	02/08/2021	achieng	
Athena Robinson PHRP Certificate	02/08/2021	achieng	
Student Wellness Listserv Permission	02/08/2021	achieng	
Stanford Staffers Listserv Permission	02/08/2021	achieng	
Woebot Crisis Language Response	02/08/2021	achieng	
Woebot Listerv Recruitment	02/08/2021	achieng	
Woebot for Substance Use Disorders - Possible Subreddits	02/08/2021	achieng	
thumbnail_woebot-header-01	02/08/2021	achieng	
thumbnail_woebot	02/08/2021	achieng	
thumbnail_woebot-header-02	02/08/2021	achieng	
thumbnail_woebot-header-04	02/08/2021	achieng	
Study Design	02/08/2021	achieng	
NIDA SUD DSMB Meeting Minutes 1.27.21	02/23/2021	achieng	
DSMB NIDA SUD Meeting Powerpoint 1.27.21	02/23/2021	achieng	
WSUDs Upcoming Survey Email Template	03/26/2021	achieng	
Phase II Education Only Content	03/26/2021	achieng	
DRA #1085 Intake Form	04/07/2021	achieng	
DRA 1085 Third Part Portion of the Intake Form	04/07/2021	achieng	
Lauren Haruno CITI Certification	04/22/2021	achieng	
NIDA_SUD_Flyer_colorful	04/22/2021	achieng	
WSUDs Phase 2 Advertising Language v2	04/22/2021	achieng	
WSUDs Phase 2 Emailing previous participants v.2	04/22/2021	achieng	
LittleDove CITI Completion Look Up	04/22/2021	achieng	

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Phase 1 Protocol: IRB-50953	04/26/2021	achieng	
WC19 Supplement Study Protocol: IRB-56439	04/26/2021	achieng	
WCovid19 trial (For reference; Not IRB 56439)	04/27/2021	achieng	
WSUDs Phase 2 CRRP Review Sub Form	04/27/2021	achieng	
WSUDs Phase 2 Scientific Protocol in Relation to COVID-19	04/27/2021	achieng	
2021-JMIR Woebot Phase I Manuscript	05/09/2021	achieng	
ICO Contract	05/09/2021	achieng	
DRA 1085 Review Email	05/19/2021	achieng	
AshleyLee CITI Certifications	06/07/2021	achieng	
EdOnly_Week1_Understanding Alcohol Use Disorder	06/16/2021	achieng	
EdOnly_Week2_What is binge drinking	06/16/2021	achieng	
EdOnly_Week3_Addiction and Health	06/16/2021	achieng	
EdOnly_Week4_Is Addiction a Disease	06/16/2021	achieng	
EdOnly_Week5_Drugs and the Brain	06/16/2021	achieng	
EdOnly_Week7_Alcohol Facts and Stat	06/16/2021	achieng	
EdOnly_Week8_Fast Facts about Addiction	06/16/2021	achieng	
Woebot Statement on 21 CFR Part 11 1.25.22	01/25/2022	achieng	
NIDA Phase II RCT Recruitment Language_Images 1.25.22	01/25/2022	achieng	
EdOnly_Week6_Drugs that People Misuse Updated Ver	01/25/2022	achieng	
NIDA SUD DSMB Meeting 6.16.21_FINAL	01/26/2022	achieng	
NIDA SUD DSMB Meeting Minutes_06.16.21	01/26/2022	achieng	

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

Woebot Phase 2 BL Survey 1.26.22	01/26/2022	achieng	
Woebot Phase 2 Survey 4wk 1.26.22	01/26/2022	achieng	
Woebot Phase 2 EOT Survey 1.26.22	01/26/2022	achieng	
Woebot Phase 2 Survey 3m 1.26.22	01/26/2022	achieng	
WSUDs Debrief Doc 7.21.21	01/26/2022	achieng	
Email template for sending out signed consent forms for the study 1.26.22	01/26/2022	achieng	
Email Template for Education Only Group Intervention Content	01/26/2022	achieng	
NIDA Phase II Participant Facing Materials and Additional Wording 3.8.22	03/08/2022	achieng	
Message Templates Related to Adobe Sign 3.8.22	03/08/2022	achieng	
WSUDs Phase 2 Instructions for Groups 2.3.22 ver3	03/08/2022	achieng	
Secure Email Template 3.8.22	03/08/2022	achieng	
WSUDs Phase 2 Manual Email Templates 3.8.22	03/08/2022	achieng	
WSUDs Qualtrics Auto Email Templates 3.8.22	03/08/2022	achieng	
Woebot Phase 2 Screening Questionnaire 3.8.22	03/08/2022	achieng	
WSUDs Phone Script 3.8.22	03/08/2022	achieng	

## Obligations

The Protocol Director agrees to:

- Adhere to principles of sound scientific research designed to yield valid results
- Conduct the study according to the protocol approved by the IRB
- Be appropriately qualified to conduct the research and be trained in Human Research protection, ethical principles, regulations, policies and procedures
- Ensure all Stanford research personnel are adequately trained and supervised
- Ensure that the rights and welfare of participants are protected including privacy and confidentiality of data

**Title :** Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use (SU sIRB)  
**Approval Period:** 04/13/2022 - 05/12/2022

- Ensure that, when de-identified materials are obtained for research purposes, no attempt will be made to re-identify them.
- Disclose to the appropriate entities any potential conflict of interest
- Report promptly any new information, modification, or unanticipated problems that raise risks to participants or others
- Apply relevant professional standards.

Any change in the research protocol must be submitted to the IRB for review prior to the implementation of such change. Any complications in participants or evidence of increase in the original estimate of risk should be reported at once to the IRB before continuing with the project. Inasmuch as the Institutional Review Board (IRB) includes faculty, staff, legal counsel, public members, and students, protocols should be written in language that can be understood by all Panel members. The investigators must inform the participants of any significant new knowledge obtained during the course of the research.

IRB approval of any project is for a maximum period of one year. For continuing projects and activities, it is the responsibility of the investigator(s) to resubmit the project to the IRB for review and re-approval prior to the end of the approval period. A Notice to Renew Protocol is sent to the Protocol Director 7 weeks prior to the expiration date of the protocol.

<https://stanfordmedicine.box.com/shared/static/qbsi8u8h47qsotxhdpuzz50xlrsa0sgo.pdf> Report promptly any new information, complaints, possibly serious and/or continuing noncompliance, or unanticipated problems involving risks to participants or others.

All data including signed consent form documents must be retained for a minimum of three years past the completion of the research. Additional requirements may be imposed by your funding agency, your department, or other entities. (Policy on Retention of and Access to Research Data, Research Policy Handbook, <http://doresearch.stanford.edu/policies/research-policy-handbook/conduct-research/retention-and-access-research-data>)

APPROVAL LETTER/NOTICE NOTE: List all items (verbatim) that you want to be included in your approval letter (e.g., Amendment date, Investigator's Brochure version, consent form(s) version(s), advertisement name, etc.) in the box below.

Y By checking this box, I verify that I, as the Protocol Director (PD) responsible for this research protocol, have read and agree to abide by the above obligations, or that I have been delegated authority by the PD to certify that the PD has read and agrees to abide by the above obligations.